Objectives: We investigated the effects of long-term endothelin A (ET ) receptor blockade and ACE inhibition, either alone or in A combination, on the hemodynamics, neurohormonal activation and cardiac remodeling in rats with congestive heart failure (CHF) after extensive myocardial infarction (MI). Methods: Rats were treated with placebo, the ET antagonist LU135252 (30 mg / kg / d), the ACE A inhibitor trandolapril (0.3 mg / kg / d), or a combination of both for 11 weeks, starting 7 days after MI. Results: Despite comparable effects on left ventricular (LV) systolic pressure among all drug treatments, only combined ET and ACE inhibition significantly reduced LV A end-diastolic pressure (P,0.01), improved LV dP/dt (P,0.01) and normalized sympathetic activation (P,0.05) in rats with CHF. The max combination therapy was more effective in reducing type I and III collagen mRNA levels, MMP-2 zymographic activity and collagen accumulation in the surviving LV myocardium. Moreover, the increases in cardiac b-myosin heavy chain and skeletal a-actin mRNAs, markers of hypertrophy or failure, were attenuated to a greater degree by the combination therapy than monotherapy, whereas right ventricular hypertrophy and ANF mRNA upregulation were significantly (P,0.01) prevented only by combined ET and ACE inhibition.
Introduction
toms and reduce overall mortality, heart failure remains a progressive disease process and is the leading cause of Left ventricular (LV) remodeling after myocardial indeath in humans. Thus, the development of novel therapeufarction (MI) involves myocyte hypertrophy and chamber tic strategies for heart failure represents an important dilation. In addition, increased collagen accumulation priority in cardiovascular medicine. remote from the infarct site increases myocardial stiffness Plasma endothelin-1 (ET-1) levels are elevated in and contractile dysfunction, and contributes to the propatients with heart failure and correlated with the severity gression of ventricular enlargement and heart failure [1] [2] [3] [4] .
of the disease [9] . In addition, the local ET system is The beneficial effects of ACE inhibitors after MI are activated in the failing heart [10, 11] and endothelin is related to peripheral vasodilatation, ventricular unloading, involved in postinfarct remodeling [10] [11] [12] [13] [14] . Whether ET A and reduction of myocyte hypertrophy and interstitial receptor antagonists provide a benefit additional to ACE fibrosis [5] [6] [7] [8] . Although ACE inhibitors improve sympinhibitor treatment in congestive heart failure (CHF) remains unknown. inhibitor (trandolapril), and their combination, on hemo-LU135252 (n56), trandolapril (n55), and the dynamics and LV remodeling (fibrosis, hypertrophy, fetal LU1352521trandolapril combination (n55). gene expression) in rats with CHF after extensive MI. In addition, we studied the effects of pharmacologic interven-2.2. Sample collection, infarct size, ventricular dilation tions on neurohormonal activation and right ventricular hypertrophy.
The heart was divided into right ventricle and LV, including septum, in ice-cold saline. The LV was cut into three transverse sections: apex, middle ring (|3 mm), and base. From the middle ring, 5-mm sections were cut at 2. Methods 100-mm intervals and stained with picrosirius red. The boundary lengths of the infarcted and non-infarcted endoThe investigation conformed with the Guide for the cardial and epicardial surfaces were traced with a planimeCare and Use of Laboratory Animals published by the US ter digital image analyser (Sony). Infarct size was calcuNational Institutes of Health (NIH publication No. 85-23, lated as the average of all slices and only rats with revised 1996). extensive infarcts (.45%) were included in the study (placebo, n58; LU135252, n57; trandolapril, n57; and 2.1. Myocardial infarction, study protocols, LU1352521trandolapril, combination, n59). LV cavity hemodynamic measurements area (area enclosed by LV endocardial circumference) normalized by body weight was taken as an index of LV Left coronary artery ligations [11] were performed in dilation [15] . adult male Wistar rats (200-250 g). Briefly, under ether anaesthesia, the thorax was opened, the heart exteriorised, 2.3. Quantification of cardiac gene expression and a ligature placed around the proximal left coronary artery. The heart was returned to its normal position and Total RNA was isolated from surviving LV (septum) and the thorax closed. Mortality was 40% within the first 24 h. right ventricular (RV) myocardium using TRIzol reagent Sham-operated controls (n510) underwent the same sur-(Life Technologies). Transforming growth factor-b (TGF-1 gical procedure except that the suture around the coronary b ), collagen a1(I) and a1(III), atrial natriuretic factor 1 artery was not tied. Of the 140 rats that had undergone left (ANF) and glyceraldehyde-3-phosphate-dehydrogenase coronary artery ligation, 66 died before the seventh (GAPDH) gene expression was determined by competitive postoperative day. Starting on the seventh postoperative polymerase chain reaction (PCR) ( Table 1) . Heterologous day, sham-operated animals received placebo treatment, internal standards were constructed with a Competitive and surviving MI rats (74) were allocated randomly to one DNA PCR Kit (Takara Shuzo) and purified using a PCR of the following four treatment groups: placebo (n520), Purification Kit (QIAGEN). Products of PCR amplification the ET antagonist LU135252 (30 mg / kg / d, n518), the were separated on 2% agarose gel. A given mRNA level A ACE inhibitor trandolapril (0.3 mg / kg / d, n518), or a was expressed as a ratio with respect to the level of mRNA combination of LU1352521trandolapril (n518) given in for GAPDH. a-and b-myosin heavy chain (MHC) mRNA drinking water according to the manufacturer's instructions and skeletal and cardiac a-actin mRNA were amplified by (Knoll AG). Twenty-three rats died after randomization PCR as previously described [16] using DIG-labeled during the 11 weeks of treatment: placebo (n57), forward primers. After digestion with the restriction en- zyme Tru9I for MHC and SacI for a-actin, fragments of cine skin) under nonreducing conditions [20] . Reverse the PCR amplification product were separated, respectivezymography was performed in a similar manner except ly, on 8% and 6% polyacrylamide gel. The ratio of b-to that purified MMP-2 (30 mg / ml, Oncogene) was incorpoa-MHC mRNA and skeletal to cardiac a-actin mRNA was rated into a 15% SDS-polyacrylamide gel along with 1 quantified using chemiluminescence. mg / ml gelatin as described [21] . Human recombinant purified enzymes (MMP-2, TIMP-2, Oncogene) were used 2.4. Myocardial hydroxyproline, collagen phenotypes as a positive control and standardization among gels. Molecular weights were determined using prestained SDSFor hydroxyproline determination, LV myocardial sam-PAGE standard and precision protein standards (Bio-Rad). ples (septum) were freeze-dried, weighed and hydrolyzed in 6 N HCl at 110 8C for 24 h. Hydroxyproline con-2.6. Neurohormonal assay centration was measured spectrophotometrically [17] . Collagen content was expressed in mg / mg dry tissue weight After hemodynamic measurement, a blood sample was assuming that collagen contains an average of 13.4%
collected from the right carotid artery. Plasma renin hydroxyproline.
activity (PRA) and aldosterone levels were measured by Collagen extraction and phenotyping was performed as radioimmunoassay (Sorin Biomedica). Plasma norepinephdescribed [18] . Briefly, after removal of the bulk of rine levels were measured with high-performance liquid noncollagen protein with SDS (2%), LV (septum) collagen chromatography and plasma ET-1 levels by radioimwas digested with cyanogen bromide in formic acid (70% munoassay, as reported [11] . vol / vol) for 18 h at 25 8C. The supernatant was dried, directly dissolved in loading buffer and electrophoresed on 2.7. Statistical analysis a 12% SDS-polyacrylamide gel. The amount loaded was determined by hydroxyproline determination. After elecStatistical analysis was performed by two-factor trophoresis, the gel was stained with Coomassie blue R250
ANOVA followed by the least-squares mean test. Correla-(0.125%). The relative amounts of type I / III collagen were tions were determined by linear regression analysis. Redetermined from the relationship between the relative area sults are reported as mean6S.E.M. P,0.05 was considunder the densitometry curve corresponding to band G ered statistically significant. LV myocardial samples (septum) were homogenized in Infarct size and body weight were similar among the ice-cold extraction buffer [19] , incubated with continuous experimental groups ( Table 2) . Trandolapril monotherapy agitation for 20 h and centrifuged at 80003g for 30 min at and combination therapy attenuated the rise in LV weight 4 8C. Proteins were determined by Bradford assay. observed in CHF placebo rats. RV weight was markedly Myocardial extracts (8 mg protein per lane) were mixed higher in placebo-treated CHF rats compared with shamwith loading buffer and electrophoresed on a 10% SDSoperated controls and was significantly reduced only by polyacrylamide gel containing gelatin (type A from porcombined ET receptor and ACE inhibition. CHF resulted A Table 2 Global parameters in rats with congestive heart failure 12 weeks after myocardial infarction compared with control in an increase in LVCA, which was significantly attenuated 3.4. Left ventricular collagen concentration and by both monotherapies and further reduced by combined phenotypic ratio ET and ACE inhibition (Table 2) .
A LV collagen concentrations were markedly increased in 3.2. Hemodynamics CHF placebo rats. Treatment with LU135252 or trandolapril alone was associated with a significant reduction in LV systolic pressure (LVSP) and mean arterial pressure collagen concentration. Combination therapy further sup-(MAP) were reduced in CHF rats on placebo compared pressed collagen accumulation in the failing LV myocarwith sham-operated animals and were slightly lowered dium (Fig. 2) . Enhanced ratios of collagen type I / III were further to a comparable degree in all active treatment observed in CHF rats compared with controls (2.4860.08 groups. Right atrial pressure (RAP) was elevated in versus 1.9660.04, P,0.005). All drug treatments siguntreated CHF rats and reduced more significantly by nificantly reduced the collagen phenotype ratio compared combination therapy than monotherapies ( sponse to CHF. The ratios of LV skeletal to cardiac a-actin mRNA and LV b-MHC to a-MHC mRNA were substanbined ET receptor and ACE inhibition. Moreover, only A tially increased in placebo CHF rats, significantly atcombined ET and ACE inhibition prevented the CHF-A tenuated by trandolapril monotherapy and further reduced associated rise in the RV ratio of skeletal to cardiac a-actin by combined ET and ACE inhibition (Fig. 3) . RV ANF mRNA (Fig. 4) . The ratio of b-MHC to a-MHC mRNA A mRNA expression was markedly higher in CHF rats than was increased in RV and significantly reduced by ACE in controls and was significantly reduced only by cominhibition alone. However, combination therapy led to a substantial further decrease in the RV b-to a-MHC ratio 4. Discussion compared with trandolapril monotherapy (Fig. 4) .
The major novel findings of this study are the following. (1) The combination of an ET receptor antagonist and an A 3.7. Plasma neurohormones ACE inhibitor reduced LV end-diastolic pressure, improved cardiac function and normalized sympathetic activation in CHF was characterized by a marked increase in PRA, rats with CHF after extensive MI. The combination was norepinephrine and endothelin-1 (Fig. 5) . PRA showed the more effective in reducing cardiac fibrosis and fetal gene highest values in both trandolapril-treated groups, conexpression than the individual drugs. (2) The rise in RV sistent with pharmacological interruption of the reninweight and ANF mRNA associated with CHF was preangiotensin system. ACE inhibition also markedly invented only by the combination. A in CHF rats compared with placebo (P50.06). Plasma norepinephrine levels tended to be reduced by LU135252 4.1. Left ventricular hemodynamics and trandolapril monotherapy, however they were only significantly decreased by combined ET receptor and Coronary artery ligation in the rat produces a broad A ACE inhibition. Plasma ET-1 levels remained elevated in spectrum of cardiac dysfunction, ranging from minor either monotherapy CHF group, whereas combination impairment to overt heart failure [7, 22] , depending on MI therapy slightly, but not significantly, reduced ET-1 levels size. Several studies in rats have demonstrated that monoin CHF rats. Plasma aldosterone levels were higher in CHF therapy with either ACE inhibitors [7, 8] or ET receptor rats than in sham-operated rats (649687 versus 292638
antagonists after MI provided beneficial effects on LV ng / g tissue, P,0.001) and were slightly, but not sighemodynamics and remodeling [10] [11] [12] [13] . In rats with nificantly, lowered by drug treatment (LU CHF, 535692; extensive MI, which mimics severe CHF, the effect of T CHF, 515685; LU1T CHF, 613659).
ACE inhibition was minor [7] . We show that the combina- receptor blockade [12, 13] . We show for the first time that ET receptor blockade effectively decreased collagen type inhibition also reversed the rise in the ratio between collagen type I and collagen type III at the protein level. It has previously been shown that ET-1 increased cardiac fibroblast collagen synthesis [28] , and activated the procollagen I promoter [29] . Moreover, involvement of ET-1 in cardiac collagen deposition in mineralocorticoid hypertension has been suggested by reduction of procollagen synthesis after ET receptor blockade [30] . Our observa-A tions provide evidence that the upregulated cardiac endothelin system plays an important role in the pathogenesis of postinfarction reactive LV fibrosis, by promoting collagen gene expression. The combination therapy most effectively normalized LV collagen expression and accumulation. Alterations in the collagen matrix raise cardiac muscle stiffness and impair LV performance, leading to progressive dysfunction and heart failure [1]. It has been proposed that fibrosis in the remote noninfarcted myocardium is a major determinant of ventricular remodeling in ischemic cardiomyopathy [2] . Therefore, the more marked improvement of LV remodeling and failure by combined ACE and ET inhibition may be mediated, in part, by the reduction A of LV fibrosis.
Upregulation of MMPs also plays an important role in LV dilation during heart failure [31, 32] . Both ET-1 and angiotensin II increase MMP activity in isolated myocytes [33] . Accordingly, in the present study the addition of the ET antagonist to ACE inhibition further reduced MMP-2 A activity in the surviving LV myocardium, thus contributing [ 16, 36] are involved in fetal gene re-expression of hypertrophic myocytes. Downregulation of a-MHC coupled tion of an ACE inhibitor and an ET receptor blocker has with upregulation of b-MHC [37, 38] has been demon-A beneficial effects on hemodynamics even in rats with strated in failing human myocardium. Enhanced expression extensive MI. Although acutely adding an ET antagonist to of fetal isoforms of contractile proteins may play a critical an ACE inhibitor further reduced blood pressure [23] [24] [25] [26] [27] role in the impairment of cardiac performance and pathowe did not observe an additive hypotensive effect after physiology of heart failure [6, 37] . Ruf et al. provided long-term treatment.
evidence that alterations of cross-bridge kinetics may reflect the mechanical and energetic consequences of a-
Left ventricular fibrosis
MHC downregulation in the failing human myocardium [39] . In the present study, combined ET receptor and [1], which is reduced by ACE inhibition [6, 8] or ET myocardium more than either monotherapy. Thus, normali-zation of the molecular phenotype and the improvement of ET-1 levels. Supporting this notion, circulating endothelin concentrations are increased and correlate with the severity myocardial failure are likely to be causally related.
of heart failure [9] . In addition, changes in circulating The effectiveness of combination therapy in preventing ET-1 levels reflect the magnitude and the direction of the RV hypertrophy may be mediated through improvement of hemodynamic and neurohormonal response to ACE in-LV failure. In fact, the hypertrophic growth of the right hibitors as well as b-blocker therapy [46, 47] . ventricle post-MI is related to LV dilation and pump Whether selective ET or mixed ET and ET receptor failure, resulting in increased pressure load on the ventricle A A B
blockade should be favored in the treatment of CHF is still [7, 22] . However, a more effective direct interference with unclear. Selective ET antagonists may offer advantages the RV renin-angiotensin system and / or endothelin system A over mixed ET and ET antagonists. ET receptor by combination therapy may have contributed to the A B B
inhibition reduces endothelin clearance and NO-mediated pronounced improvement of RV remodeling.
vasodilatation [14] . In addition, ET receptor inhibition B Several studies have reported a link between the reninmay abrogate the beneficial effects of ET receptor A angiotensin and endothelin systems. ET-1 is involved in blockade on vascular superoxide formation [43] . However, angiotensin II-induced hypertrophy in cultured carMulder et al. [13] reported that the inhibition of both ET A diomyocytes [40] . an endothelin-related mechanism [42] . This is compatible ACE inhibition may have important clinical implications with our present findings in rats with CHF.
for patients with CHF. Although to date there are no clinical endpoint studies using ET antagonists in CHF 4.4. Neurohumoral activation patients, several short-term studies demonstrate hemodynamic and symptomatic improvement [14, 25, 27, 48, 49] . In the present study, consistent with past reports [43, 44] , ET receptor blockade causes pulmonary vasodilation [50] A ET receptor inhibition lowered plasma renin activity in A and reduces forearm vascular resistance in CHF patients rats with CHF. The underlying mechanisms may include treated with ACE inhibitors [24, 26] . However, long-term indirect effects on renin release secondary to improvement studies investigating the effects of combination therapy of renal perfusion [45] and / or decreased sympathetic with ET antagonists and ACE inhibitors on cardiac reactivation. A direct effect of ET receptor blockade A modeling are lacking. appears unlikely as, in other models with high renin Our work provides experimental evidence that long-term activity, ET antagonism did not affect plasma renin A combined ET receptor and ACE inhibition improves A activity [42] . myocardial failure and prevents fibrosis and fetal gene In the present study, plasma norepinephrine levels expression more effectively than either monotherapy. tended to be reduced by ET receptor blockade and ACE A Thus, ET receptor blockers may be useful when added to A inhibition alone, but were significantly suppressed only by ACE inhibitors in patients with CHF. the combination therapy. Hemodynamic improvement likely accounted for reflex inhibition of sympathetic activation. New et al. [44] also reported that combined AT and ET 1
